Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders
From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2003, Vol.39 (4), p.488-494 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 494 |
|---|---|
| container_issue | 4 |
| container_start_page | 488 |
| container_title | European journal of cancer (1990) |
| container_volume | 39 |
| creator | Smeland, S Müller, C Alvegard, T.A Wiklund, T Wiebe, T Björk, O Stenwig, A.E Willén, H Holmström, T Follerås, G Brosjö, O Kivioja, A Jonsson, K Monge, O Sæter, G |
| description | From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume 4.5 μM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in >70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. |
| doi_str_mv | 10.1016/S0959-8049(02)00747-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_589862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804902007475</els_id><sourcerecordid>73304955</sourcerecordid><originalsourceid>FETCH-LOGICAL-e402t-28496789dfe2d3d09f1c5013b13a3b56a354b9a9492b40b3cbb0f4c26ca83c3f3</originalsourceid><addsrcrecordid>eNp1kk2P0zAQhiMEYsvCTwD5AoJDwB9xYnNBaAWlUqU9BLhatjNuDWmctZOi_iN-Ju4Hy4nD2Nbomdf2zFsUzwl-SzCp37VYclkKXMnXmL7BuKmakj8oFkQ0ssSC04fF4h65Kp6k9ANnSlT4cXFFaMMJE3hR_G6tHjo_6L3XA2p1tGGn0TKGeUS3aYKQLql2mrsDatsl-r5ard6jMYbNENLkLXLaTiEm5EJEYZ4yDiiLomkLKIYeUHAowthrCzsYJpR0v9cbQHYLu5ChqMfDqXgMedn6NIU-bLzVfS5LYxg6iOlp8cjpPsGzy35dfPv86evNl3J9u1zdfFyXUGE6lVRUsm6E7BzQjnVYOmI5JswQppnhtWa8MlLLSlJTYcOsMdhVltZWC2aZY9dFedZNv2CcjRqj3-l4UEF7dUn9zCdQXEhR08yv_8v385jD5DgWGEuddHWtHKONqiTBOSVA1ZYQ0lkpDO-y3KuzXO7v3QxpUjufLPS9HiDMSTWM5XlynsEXF3A2O-ju7_072gy8vAA65Va6qAfr0z-u4o3MX8jchzMHuat7D1El62Gw0PkIdlJd8Co_9Wg6dTKdOjpKYapOplOc_QEt38w8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73304955</pqid></control><display><type>article</type><title>Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>SWEPUB Freely available online</source><creator>Smeland, S ; Müller, C ; Alvegard, T.A ; Wiklund, T ; Wiebe, T ; Björk, O ; Stenwig, A.E ; Willén, H ; Holmström, T ; Follerås, G ; Brosjö, O ; Kivioja, A ; Jonsson, K ; Monge, O ; Sæter, G</creator><creatorcontrib>Smeland, S ; Müller, C ; Alvegard, T.A ; Wiklund, T ; Wiebe, T ; Björk, O ; Stenwig, A.E ; Willén, H ; Holmström, T ; Follerås, G ; Brosjö, O ; Kivioja, A ; Jonsson, K ; Monge, O ; Sæter, G</creatorcontrib><description>From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume <190 ml, 24-h serum methotrexate >4.5 μM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in >70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome.</description><identifier>ISSN: 0959-8049</identifier><identifier>ISSN: 1879-0852</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(02)00747-5</identifier><identifier>PMID: 12751380</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Bone Neoplasms - drug therapy ; Bone Neoplasms - pathology ; Bone Neoplasms - surgery ; Cancer and Oncology ; Cancer och onkologi ; Chemotherapy ; Chemotherapy, Adjuvant ; Child ; Child, Preschool ; Cisplatin - administration & dosage ; Clinical Medicine ; Clinical protocols ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Doxorubicin - administration & dosage ; Female ; Humans ; Infant ; Infant, Newborn ; Klinisk medicin ; Limb salvage ; Male ; Medical and Health Sciences ; Medical sciences ; Medicin och hälsovetenskap ; Methotrexate - administration & dosage ; Middle Aged ; Neo-adjuvant therapy ; Neoplasm Recurrence, Local ; Osteosarcoma ; Osteosarcoma - drug therapy ; Osteosarcoma - pathology ; Osteosarcoma - surgery ; Patient Compliance ; Pediatrics ; Pediatrik ; Pharmacology. Drug treatments ; Prognosis ; Radiologi och bildbehandling ; Radiology, Nuclear Medicine and Medical Imaging ; Salvage Therapy ; Scandinavia ; Sex ; Survival Analysis</subject><ispartof>European journal of cancer (1990), 2003, Vol.39 (4), p.488-494</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0959804902007475$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,550,776,780,881,3537,4010,27900,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14579898$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12751380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/315438$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1938907$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Smeland, S</creatorcontrib><creatorcontrib>Müller, C</creatorcontrib><creatorcontrib>Alvegard, T.A</creatorcontrib><creatorcontrib>Wiklund, T</creatorcontrib><creatorcontrib>Wiebe, T</creatorcontrib><creatorcontrib>Björk, O</creatorcontrib><creatorcontrib>Stenwig, A.E</creatorcontrib><creatorcontrib>Willén, H</creatorcontrib><creatorcontrib>Holmström, T</creatorcontrib><creatorcontrib>Follerås, G</creatorcontrib><creatorcontrib>Brosjö, O</creatorcontrib><creatorcontrib>Kivioja, A</creatorcontrib><creatorcontrib>Jonsson, K</creatorcontrib><creatorcontrib>Monge, O</creatorcontrib><creatorcontrib>Sæter, G</creatorcontrib><title>Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume <190 ml, 24-h serum methotrexate >4.5 μM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in >70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - surgery</subject><subject>Cancer and Oncology</subject><subject>Cancer och onkologi</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cisplatin - administration & dosage</subject><subject>Clinical Medicine</subject><subject>Clinical protocols</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Doxorubicin - administration & dosage</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Klinisk medicin</subject><subject>Limb salvage</subject><subject>Male</subject><subject>Medical and Health Sciences</subject><subject>Medical sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Methotrexate - administration & dosage</subject><subject>Middle Aged</subject><subject>Neo-adjuvant therapy</subject><subject>Neoplasm Recurrence, Local</subject><subject>Osteosarcoma</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - pathology</subject><subject>Osteosarcoma - surgery</subject><subject>Patient Compliance</subject><subject>Pediatrics</subject><subject>Pediatrik</subject><subject>Pharmacology. Drug treatments</subject><subject>Prognosis</subject><subject>Radiologi och bildbehandling</subject><subject>Radiology, Nuclear Medicine and Medical Imaging</subject><subject>Salvage Therapy</subject><subject>Scandinavia</subject><subject>Sex</subject><subject>Survival Analysis</subject><issn>0959-8049</issn><issn>1879-0852</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp1kk2P0zAQhiMEYsvCTwD5AoJDwB9xYnNBaAWlUqU9BLhatjNuDWmctZOi_iN-Ju4Hy4nD2Nbomdf2zFsUzwl-SzCp37VYclkKXMnXmL7BuKmakj8oFkQ0ssSC04fF4h65Kp6k9ANnSlT4cXFFaMMJE3hR_G6tHjo_6L3XA2p1tGGn0TKGeUS3aYKQLql2mrsDatsl-r5ard6jMYbNENLkLXLaTiEm5EJEYZ4yDiiLomkLKIYeUHAowthrCzsYJpR0v9cbQHYLu5ChqMfDqXgMedn6NIU-bLzVfS5LYxg6iOlp8cjpPsGzy35dfPv86evNl3J9u1zdfFyXUGE6lVRUsm6E7BzQjnVYOmI5JswQppnhtWa8MlLLSlJTYcOsMdhVltZWC2aZY9dFedZNv2CcjRqj3-l4UEF7dUn9zCdQXEhR08yv_8v385jD5DgWGEuddHWtHKONqiTBOSVA1ZYQ0lkpDO-y3KuzXO7v3QxpUjufLPS9HiDMSTWM5XlynsEXF3A2O-ju7_072gy8vAA65Va6qAfr0z-u4o3MX8jchzMHuat7D1El62Gw0PkIdlJd8Co_9Wg6dTKdOjpKYapOplOc_QEt38w8</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Smeland, S</creator><creator>Müller, C</creator><creator>Alvegard, T.A</creator><creator>Wiklund, T</creator><creator>Wiebe, T</creator><creator>Björk, O</creator><creator>Stenwig, A.E</creator><creator>Willén, H</creator><creator>Holmström, T</creator><creator>Follerås, G</creator><creator>Brosjö, O</creator><creator>Kivioja, A</creator><creator>Jonsson, K</creator><creator>Monge, O</creator><creator>Sæter, G</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D95</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>2003</creationdate><title>Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders</title><author>Smeland, S ; Müller, C ; Alvegard, T.A ; Wiklund, T ; Wiebe, T ; Björk, O ; Stenwig, A.E ; Willén, H ; Holmström, T ; Follerås, G ; Brosjö, O ; Kivioja, A ; Jonsson, K ; Monge, O ; Sæter, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e402t-28496789dfe2d3d09f1c5013b13a3b56a354b9a9492b40b3cbb0f4c26ca83c3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - surgery</topic><topic>Cancer and Oncology</topic><topic>Cancer och onkologi</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cisplatin - administration & dosage</topic><topic>Clinical Medicine</topic><topic>Clinical protocols</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Doxorubicin - administration & dosage</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Klinisk medicin</topic><topic>Limb salvage</topic><topic>Male</topic><topic>Medical and Health Sciences</topic><topic>Medical sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Methotrexate - administration & dosage</topic><topic>Middle Aged</topic><topic>Neo-adjuvant therapy</topic><topic>Neoplasm Recurrence, Local</topic><topic>Osteosarcoma</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - pathology</topic><topic>Osteosarcoma - surgery</topic><topic>Patient Compliance</topic><topic>Pediatrics</topic><topic>Pediatrik</topic><topic>Pharmacology. Drug treatments</topic><topic>Prognosis</topic><topic>Radiologi och bildbehandling</topic><topic>Radiology, Nuclear Medicine and Medical Imaging</topic><topic>Salvage Therapy</topic><topic>Scandinavia</topic><topic>Sex</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smeland, S</creatorcontrib><creatorcontrib>Müller, C</creatorcontrib><creatorcontrib>Alvegard, T.A</creatorcontrib><creatorcontrib>Wiklund, T</creatorcontrib><creatorcontrib>Wiebe, T</creatorcontrib><creatorcontrib>Björk, O</creatorcontrib><creatorcontrib>Stenwig, A.E</creatorcontrib><creatorcontrib>Willén, H</creatorcontrib><creatorcontrib>Holmström, T</creatorcontrib><creatorcontrib>Follerås, G</creatorcontrib><creatorcontrib>Brosjö, O</creatorcontrib><creatorcontrib>Kivioja, A</creatorcontrib><creatorcontrib>Jonsson, K</creatorcontrib><creatorcontrib>Monge, O</creatorcontrib><creatorcontrib>Sæter, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Lunds universitet</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smeland, S</au><au>Müller, C</au><au>Alvegard, T.A</au><au>Wiklund, T</au><au>Wiebe, T</au><au>Björk, O</au><au>Stenwig, A.E</au><au>Willén, H</au><au>Holmström, T</au><au>Follerås, G</au><au>Brosjö, O</au><au>Kivioja, A</au><au>Jonsson, K</au><au>Monge, O</au><au>Sæter, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2003</date><risdate>2003</risdate><volume>39</volume><issue>4</issue><spage>488</spage><epage>494</epage><pages>488-494</pages><issn>0959-8049</issn><issn>1879-0852</issn><eissn>1879-0852</eissn><abstract>From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume <190 ml, 24-h serum methotrexate >4.5 μM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in >70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12751380</pmid><doi>10.1016/S0959-8049(02)00747-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2003, Vol.39 (4), p.488-494 |
| issn | 0959-8049 1879-0852 1879-0852 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_589862 |
| source | MEDLINE; Elsevier ScienceDirect Journals; SWEPUB Freely available online |
| subjects | Adolescent Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Neoplasms - drug therapy Bone Neoplasms - pathology Bone Neoplasms - surgery Cancer and Oncology Cancer och onkologi Chemotherapy Chemotherapy, Adjuvant Child Child, Preschool Cisplatin - administration & dosage Clinical Medicine Clinical protocols Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Doxorubicin - administration & dosage Female Humans Infant Infant, Newborn Klinisk medicin Limb salvage Male Medical and Health Sciences Medical sciences Medicin och hälsovetenskap Methotrexate - administration & dosage Middle Aged Neo-adjuvant therapy Neoplasm Recurrence, Local Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - pathology Osteosarcoma - surgery Patient Compliance Pediatrics Pediatrik Pharmacology. Drug treatments Prognosis Radiologi och bildbehandling Radiology, Nuclear Medicine and Medical Imaging Salvage Therapy Scandinavia Sex Survival Analysis |
| title | Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A25%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Scandinavian%20Sarcoma%20Group%20Osteosarcoma%20Study%20SSG%20VIII:%20prognostic%20factors%20for%20outcome%20and%20the%20role%20of%20replacement%20salvage%20chemotherapy%20for%20poor%20histological%20responders&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Smeland,%20S&rft.date=2003&rft.volume=39&rft.issue=4&rft.spage=488&rft.epage=494&rft.pages=488-494&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(02)00747-5&rft_dat=%3Cproquest_swepu%3E73304955%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73304955&rft_id=info:pmid/12751380&rft_els_id=S0959804902007475&rfr_iscdi=true |